title: Therapeutic activity of pretazettine on Rauscher leukemia: combination of antiviral activity and cellular protein inhibition.
abstract: Pretazettine hydrochloride (PTZ) has been found to inhibit protein synthesis, without being inhibitory to DNA and RNA, in Rauscher leukemic blood cells in mice for at least 6 h after its administration. With comparison to Virazole and cycloheximide, the specific anti-Rauscher virus activity of PTZ has been demonstrated only in acutely-infected NIH/3T3 cells but not in chronically-infected cells. It is not certain that the inhibitory action of PTZ on reverse transcriptase is contributory to its therapeutic activity in leukemic mice.
mesh_terms: D000470:Alkaloids / Q000627:therapeutic use*; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002460:Cell Line; D003601:Cytotoxicity Tests, Immunologic; D004273:DNA, Neoplasm / Q000096:biosynthesis; D004259:DNA-Directed DNA Polymerase / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D007942:Leukemia, Experimental / Q000188:drug therapy*; D046911:Macromolecular Substances; D051379:Mice; D009363:Neoplasm Proteins / Q000096:biosynthesis; D012334:RNA, Neoplasm / Q000096:biosynthesis; D011925:Rauscher Virus / Q000187:drug effects
chemical_list: D000470:Alkaloids; D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D046911:Macromolecular Substances; D009363:Neoplasm Proteins; D012334:RNA, Neoplasm; D004259:DNA-Directed DNA Polymerase